- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07227012
Un estudio para conocer el medicamento de estudio denominado PF-08634404 como tratamiento único y en combinación en participantes adultos con un cáncer de hígado denominado carcinoma hepatocelular, que está demasiado avanzado para ser extirpado mediante cirugía y puede haberse extendido a otras partes del cuerpo.
UN ESTUDIO INTERVENCIONISTA ABIERTO DE FASE 1B/2 PARA EVALUAR LA SEGURIDAD, FARMACOCINÉTICA Y EFICACIA PRELIMINAR DE PF-08634404 COMO MONOTERAPIA Y TERAPIA COMBINADA EN PARTICIPANTES ADULTOS CON CARCINOMA HEPATOCELULAR LOCALMENTE AVANZADO IRRESECABLE O METASTÁSICO
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
- Be 18 years or older.
- Have locally advanced or metastatic HCC.
- Is not a candidate for complete surgical or loco-regional therapies.
- Have not received any whole-body treatment for HCC.
Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Pfizer CT.gov Call Center
- Número de teléfono: 1-800-718-1021
- Correo electrónico: ClinicalTrials.gov_Inquiries@pfizer.com
Ubicaciones de estudio
-
-
California
-
Irvine, California, Estados Unidos, 92612
- Reclutamiento
- Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Irvine, California, Estados Unidos, 92612
- Reclutamiento
- UCI Health - Irvine Infusion Pharmacy ACC
-
Irvine, California, Estados Unidos, 92612
- Reclutamiento
- UCI Health - Irvine
-
Los Angeles, California, Estados Unidos, 90033
- Reclutamiento
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, Estados Unidos, 90033
- Reclutamiento
- Keck Hospital of USC
-
Los Angeles, California, Estados Unidos, 90033
- Reclutamiento
- USC/Norris Comprehensive Cancer Center / Investigational Drug Services
-
Los Angeles, California, Estados Unidos, 90033
- Reclutamiento
- Los Angeles General Medical Center
-
Los Angeles, California, Estados Unidos, 90025
- Reclutamiento
- START Los Angeles, LLC
-
Los Angeles, California, Estados Unidos, 90067
- Reclutamiento
- LACN Century City
-
Orange, California, Estados Unidos, 92868
- Reclutamiento
- UC Irvine Health - Chao Family Comprehensive Cancer Center
-
Pasadena, California, Estados Unidos, 91105
- Reclutamiento
- Keck Medical Center of USC Pasadena
-
-
Florida
-
Land O' Lakes, Florida, Estados Unidos, 34638
- Reclutamiento
- Moffitt Cancer Center at Speros
-
Ruskin, Florida, Estados Unidos, 33570
- Reclutamiento
- Moffitt Cancer Center at SouthShore
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center - McKinley Campus
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt McKinley Hospital
-
Tampa, Florida, Estados Unidos, 33607
- Reclutamiento
- Moffitt Cancer Center - International Plaza
-
Wesley Chapel, Florida, Estados Unidos, 33544
- Reclutamiento
- Moffitt Cancer Center at Wesley Chapel
-
-
Illinois
-
Shiloh, Illinois, Estados Unidos, 62269
- Reclutamiento
- Siteman Cancer Center - Shiloh
-
Shiloh, Illinois, Estados Unidos, 62269
- Reclutamiento
- Memorial Hospital
-
-
Minnesota
-
Coon Rapids, Minnesota, Estados Unidos, 55433
- Reclutamiento
- Allina Health Cancer Institute - Mercy Hospital
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Reclutamiento
- Allina Health Cancer Institute - Abbott Northwestern Hospital
-
Saint Paul, Minnesota, Estados Unidos, 55102
- Reclutamiento
- Allina Health Cancer Institute - United Hospital
-
-
Missouri
-
City of Saint Peters, Missouri, Estados Unidos, 63376
- Reclutamiento
- Siteman Cancer Center - St. Peters
-
Creve Coeur, Missouri, Estados Unidos, 63141
- Reclutamiento
- Siteman Cancer Center - West County
-
Florissant, Missouri, Estados Unidos, 63031
- Reclutamiento
- Siteman Cancer Center - North County
-
Kansas City, Missouri, Estados Unidos, 64111
- Reclutamiento
- Saint Luke's Hospital of Kansas City
-
Kansas City, Missouri, Estados Unidos, 64111
- Reclutamiento
- Saint Luke's Cancer Institute
-
St Louis, Missouri, Estados Unidos, 63108
- Reclutamiento
- Siteman Cancer Center
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Washington University School of Medicine - Siteman Cancer Center
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Barnes-Jewish Hospital
-
St Louis, Missouri, Estados Unidos, 63129
- Reclutamiento
- Siteman Cancer Center - South County
-
-
Nevada
-
Reno, Nevada, Estados Unidos, 89502
- Reclutamiento
- Renown Regional Medical Center
-
Reno, Nevada, Estados Unidos, 89502
- Reclutamiento
- Renown Health Medical Oncology
-
Reno, Nevada, Estados Unidos, 89502
- Reclutamiento
- Renown Office of Clinical Research
-
-
North Carolina
-
Cary, North Carolina, Estados Unidos, 27518
- Reclutamiento
- Duke Cancer Center Cary
-
Durham, North Carolina, Estados Unidos, 27710
- Reclutamiento
- Duke Cancer Center
-
Durham, North Carolina, Estados Unidos, 27710
- Reclutamiento
- Duke University - Main Hospital and Clinics
-
Durham, North Carolina, Estados Unidos, 27710
- Reclutamiento
- Duke Cancer Center - Investigational Chemotherapy Service
-
Raleigh, North Carolina, Estados Unidos, 27609
- Reclutamiento
- Duke Cancer Center Raleigh
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Reclutamiento
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15212
- Reclutamiento
- AHN Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15212
- Reclutamiento
- AHN Cancer Institute at Allegheny General Hospital
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98101
- Reclutamiento
- Virginia Mason Medical Center
-
Seattle, Washington, Estados Unidos, 98109
- Reclutamiento
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Estados Unidos, 98195
- Reclutamiento
- University of Washington Medical Center- Montlake
-
-
-
-
-
Fukuoka, Japón, 811-1395
- Reclutamiento
- National Hospital Organization Kyushu Cancer Center
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japón, 464-8681
- Reclutamiento
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa, Chiba, Japón, 277-8577
- Reclutamiento
- National Cancer Center Hospital East
-
-
Osaka
-
Sakai, Osaka, Japón, 590-0197
- Reclutamiento
- Kindai University Hospital- Osaka Medical Campus
-
-
Tokyo
-
Chuo-ku, Tokyo, Japón, 104-0045
- Reclutamiento
- National Cancer Center Hospital
-
-
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 200032
- Reclutamiento
- Zhongshan Hospital,Fudan University
-
-
-
-
-
San Juan, Puerto Rico, 00909
- Reclutamiento
- Pan American Center for Oncology Trials, LLC
-
-
United States of America
-
Dorado, United States of America, Puerto Rico, 00646
- Reclutamiento
- Pan American Center for Oncology Trials, LLC - Dorado Office
-
Mayagüez, United States of America, Puerto Rico, 00680
- Reclutamiento
- Pan American Center for Oncology Trials, LLC - Mayaguez Office
-
Ponce, United States of America, Puerto Rico, 00730
- Reclutamiento
- Pan American Center for Oncology Trials, LLC - Ponce Office
-
-
-
-
-
Taichung, Taiwán, 407
- Reclutamiento
- Taichung Veterans General Hospital
-
Tainan, Taiwán, 704
- Reclutamiento
- National Cheng Kung University Hospital
-
Taipei, Taiwán, 10002
- Reclutamiento
- National Taiwan University Hospital
-
Taipei, Taiwán, 112
- Reclutamiento
- Taipei Veterans General Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 18 years of age or older at screening.
- Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
- Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
- At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.
- Adequate hepatic, liver, and renal function
- No prior systemic therapy for HCC.
- ECOG performance status 0 or 1
- Child-Pugh Class A
Key Exclusion Criteria:
- Moderate or severe ascites.
- History of hepatic encephalopathy.
- Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
- Clinically significant risk of hemorrhage or fistula.
- Participants with any history of another malignancy within 3 years.
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.
- Clinically significant cardiovascular disease within 6 months prior to the first dose.
- Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
- History of severe bleeding tendency or coagulation dysfunction.
- History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
- Participants with acute, chronic or symptomatic infections.
- Participants with history of immunodeficiency.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Phase 1b
Participants will be allocated to sequential dose levels of PF-08634404 and ipilimumab. |
Solution for infusion Solution for infusion
Otros nombres:
|
|
Experimental: Phase 2
Participants will be randomized to receive either PF-08634404 monotherapy or PF-08634404 combined with ipilimumab. |
Solution for infusion Solution for infusion
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Adverse Events
Periodo de tiempo: Through end of study and up to approximately 24 months
|
Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through end of study and up to approximately 24 months
|
|
Phase 1b: Number of participants with Dose limiting toxicities (DLT)
Periodo de tiempo: Through 90 days after the last dose of study intervention; Approximately 24 months
|
DLTs are a predefined set of adverse events that are at least possibly related to any or all of the study interventions. The number of participants who experienced DLTs during the DLT observation period. |
Through 90 days after the last dose of study intervention; Approximately 24 months
|
|
Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator
Periodo de tiempo: Approximately 24 months
|
ORR is the proportion of participants with a best overall response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab
Periodo de tiempo: Approximately 24 months
|
The doses of PF-08634404 and ipilimumab selected to be used in combination based on safety, tolerability, pharmacokinetics, and initial anti-tumor efficacy from Phase 2. |
Approximately 24 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Phase 1b: Confirmed Objective Response Rate (ORR) using RECIST 1.1 as assessed by investigator
Periodo de tiempo: Approximately 24 months
|
ORR is the proportion of participants with a best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Duration of Response (DOR) per RECIST 1.1 by investigator
Periodo de tiempo: Approximately 24 months
|
DOR is the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Progression Free Survival (PFS) per RECIST 1.1 by investigator
Periodo de tiempo: Approximately 24 months
|
PFS is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Overall Survival (OS)
Periodo de tiempo: Approximately 24 months
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 24 months
|
|
Number of Participants With Clinical Laboratory Abnormalities
Periodo de tiempo: Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing |
Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
|
Pharmacokinetics (PK): Serum concentrations of PF-08634404
Periodo de tiempo: Up to 24 months
|
Predose and/or postdose concentrations of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
|
Incidence of antidrug antibody against PF-08634404
Periodo de tiempo: Up to 24 months
|
To evaluate immunogenicity of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Pfizer CT.gov Call Center, Pfizer
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades del HIGADO
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Carcinoma
- Carcinoma Hepatocelular
- Neoplasias Hepaticas
- Aminoácidos, péptidos y proteínas
- Proteínas
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Ipilimumab
Otros números de identificación del estudio
- C6461013
- 2025-523525-17-00 (Ctis)
- Symbiotic-GI-13 (Otro identificador: Pfizer)
- 2025 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .